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UbiquitinSQSTM1mutations are common in patients with Paget disease of bone (PDB), withmost affecting the C-terminal
ubiquitin-associated (UBA) domain of the SQSTM1 protein. We performed structural and functional analyses of
two UBA domain mutations, an I424S mutation relatively common in UK PDB patients, and an A427D mutation
associatedwith a severe phenotype in Southern Italian patients. Both impaired SQSTM1's ubiquitin-binding func-
tion in pull-down assays and resulted in activation of basal NF-κB signalling, compared to wild-type, in reporter
assays.We found evidence for a relationship between the ability of different UBA domainmutants to activate NF-
κB signalling in vitro and number of affected sites in vivo in 1152PDBpatients from theUKand Italy, with A427D-
SQSTM1 producing the greatest level of activation (relative to wild-type) of all PDBmutants tested to date. NMR
and isothermal titration calorimetry studies were able to demonstrate that I424S is associated with global struc-
tural changes in the UBA domain, resulting in 10-fold weaker UBA dimer stability than wild-type and reduced
ubiquitin-binding afﬁnity of the UBA monomer. Our observations provide insights into the role of SQSTM1-
mediated NF-κB signalling in PDB aetiology, and demonstrate that different mutations in close proximity within
loop 2/helix 3 of the SQSTM1 UBA domain exert distinct effects on protein structure and stability, including indi-
rect effects at the UBA/ubiquitin-binding interface.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Paget disease of the bone (PDB; OMIM 60208) is a chronic disorder
in which increased osteoclast activity, accompanied by secondary in-
creases in osteoblast activity, leads to focal increases in bone turnover
at different sites throughout the skeleton [1]. There is a wide variation
in disease severitywithin PDBpatients; whilst some remain asymptom-
atic, others present with a range of symptoms including bone pain, sus-
ceptibility to fracture and deformity. PDB aetiology is thought to involve
a complex interplay between genetic and environmental factors. The
most important genetic link to PDB identiﬁed so far came fromposition-
al cloning studies of patients with familial PDB, where mutations affect-
ing the C-terminal ubiquitin-associated (UBA) domain of the SQSTM144 115 823 0142.
ayﬁeld).
. This is an open access article underprotein were identiﬁed [2,3]. Numerous truncating and missense
SQSTM1mutations have now been discovered [2–16] and are PDB spe-
ciﬁc; patients with mutations in SQSTM1 are on average diagnosed with
PDB5 years earlier than patientswithout [15]. Further, the skeletal phe-
notype of a mouse model of PDB carrying a P394L missense mutation,
equivalent to the most common PDB-associated P392L human muta-
tion, supports the causal role of SQSTM1 mutations in PDB aetiology
[17]. However, recent genome-wide association studies (GWAS) have
identiﬁed variants close to or within other genes (CSF1, OPTN, PML,
RIN3, NUP205, TM7SF4, and TNFRSF11A) which also signiﬁcantly act as
risk factors for PDB [18,19] and disease severity [20].
The SQSTM1 protein is involved in several distinct cellular pathways
but of particular relevance to PDB is its role in receptor activator of nu-
clear factor κB (RANK)-NF-κB signalling, which is important for osteo-
clast differentiation and function [21]. A number of studies indicate
that UBA domain mutations of SQSTM1 impair its ability to bind tothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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have provided structural insights into some of these effects [24]. In par-
ticular we noted that different PDB mutations impact on ubiquitin rec-
ognition by the UBA domain via distinct mechanisms that either affect
UBA domain structural integrity and/or UBA dimer stability, or perturb
key contacts at the UBA–ubiquitin interface [24]. In addition we and
others [7,22] noted that changes in SQSTM1's ability to regulate NF-κB
signalling may be related to disease severity in PDB patients. Notably,
truncatingmutants of SQSTM1, which earlier genotype–phenotype anal-
yses suggested to be associated with more severe PDB than common
missensemutants [6,7,25]were found to be associatedwith a greater ac-
tivation of basal NF-κB activity in reporter assays than themissensemu-
tants analysed [22]. Further support for such a relationship came from
observations that a non-synonymous variant (T575C, V192A) of RANK
(encodedby TNFRSF11A) associatedwith PDB severity in Italianpatients,
in reporter assays synergises with wild-type and PDB-mutant SQSTM1
to produce a level of activation of NF-κB signalling greater than with
RANK-V192 [26]. Whilst a recent study conﬁrms that risk alleles previ-
ously found to predispose to PDBbyGWAS are associated (in an additive
manner with SQSTM1 mutations) with disease extent and severity in
several populations, notably SQSTM1 mutation status alone plays a
major role in determining the disease phenotype in PDB patients [20].
Here, we present structural and functional analyses of the PDB-
associated I424S and A427D UBA domain mutants of SQSTM1 [14,15].
Both mutations were recently identiﬁed in independent studies and
are localised close to the site of the PDB-associatedG425Rmissensemu-
tation, whichmaps to a solvent exposed site in loop 2 of the three-helix
bundle UBA domain, and which we have previously characterised in
structural detail [24]. The UBA domain of SQSTM1 forms a highly stable
dimer involving residues largely along helix 2, but also at the C-
terminus of helix 3 [27,28]. The latter also forms part of the ubiquitin-
binding surface such that dimerisation of the UBA partially occludes
the ubiquitin-binding surface making UBA dimerisation and ubiquitin-
bindingmutually exclusive processes [27]. Of interest, we previously re-
ported that theG425Rmutation exerts only local effects onUBAdomain
tertiary structure but is associated with an increase in dimer stability
which may in part rationalise the inhibitory effects of the mutation ob-
served in ubiquitin-binding assays [29].
The I424S mutation, which is immediately adjacent to the G425 site,
but is buried in the hydrophobic core of the protein, was identiﬁed in
thePRISMstudy fromUKpatientswhoconsented toprovideDNAsamples
for analysis. The mutation was identiﬁed in a randomised trial comparing
the effects of symptomatic treatmentwith intensive bisphosphonate ther-
apy in a cohort of 1324 patients with PDB [15,30]. Within this cohort, 80
PDB patients were found to carry SQSTM1mutations, 5 of which carried
the I424S substitution alone and one with an I424S/G425R double muta-
tion. I424S therefore constitutes a relatively common PDB-associated
SQSTM1 mutation in the UK, occurring in 7.5% of the patients in the
PRISM studywith SQSTM1mutations. The A427Dmutationwas identiﬁed
in two individuals of a southern Italian family [14]. Thismutation is located
in close proximity to I424/G425, within helix 3 of the UBA domain, and
notably is associated with a high number of affected sites, with both
reported cases presenting as polyostotic PDB with 7.00 ± 2.8 affected
sites compared to 3.60±2.6 sites in SQSTM1mutation carriers collectively
within the cohort [14]. Although located in close proximity in the primary
and tertiary structure of the SQSTM1 UBA domain within the loop 2/helix
3 region, we show that the three PDB-associated mutations I424S, G425R
and A427D, exert very different effects on protein structure and function.
2. Materials and methods
2.1. Plasmids
The plasmids for expression of the full-length wild-type and G425R
mutant SQSTM1 protein (residues 1–440) and UBA domain only (resi-
dues 387–436) as GST fusion proteins (pGEX-4T-1, GE Healthcare) inEscherichia coli were described previously [22,29,31]. The I424S and
A427D mutants were produced from the wild-type plasmids by site-
directed mutagenesis (QuikChange kit; Stratagene) and subsequently
veriﬁed by DNA sequencing. Mammalian expression vectors (pcDNA3.1
construct; Invitrogen) for wild-type and selected PDB-mutant SQSTM1
proteins (His-FLAG tagged) were generated previously [22]. The I424S
andA427Dmutations (aswell as other SQSTM1mutations)were again in-
troduced into thewild-type SQSTM1 construct by site-directedmutagen-
esis and conﬁrmed by DNA sequencing.
2.2. Ubiquitin pull-down assays
Ubiquitin pull-down assays of GST-SQSTM1 proteins were per-
formed as described previously [31]. Brieﬂy, the proteins were
expressed in 10 ml cultures of E. coli and cells were lysed by sonicating
in 1 ml TBS-T buffer (10 mM Tris, 150 mM NaCl, 0.1% v/v Triton X-100,
pH 7.5). The lysed cells were centrifuged at 13,000 rpm for 10 min at
room temperature and the cleared supernatants were diluted 1:10 in
TBS-T buffer. 1 ml of each diluted lysate was incubated at 37 °C with ei-
ther excess glutathione-Sepharose (GE Healthcare), ubiquitin-
Sepharose (10 mg/ml bovine ubiquitin immobilised on CNBr-activated
Sepharose 4B) or control-Sepharose (CNBr-activated Sepharose pre-
pared without ubiquitin). The unbound proteins were then removed
and the beads washed with 3 × 1 ml TBS-T buffer at 37 °C. Bound pro-
teins were eluted from the beads with 50 μl of SDS PAGE loading buffer.
Bound proteinswere revealed bywestern blottingwith themouse anti-
SQSTM1 lck ligand antibody (BD Biosciences Pharmingen). Each assay
was repeated on a minimum of 4 independent occasions.
2.3. Cell transfection and NF-κB reporter assays
The same protocol as described previously using a NF-κB reporter that
contained the−415/−93 fragment of the human IL8 promoter cloned
into the KpnI and HindIII restriction sites of the pGL4.10 basic plasmid
(Promega) was followed [22]. Brieﬂy, HEK293T cells were cultured
in 24-well plates. 24 h after the cells were seeded they were co-
transfected with 0.2 ng/well of control Renilla luciferase plasmid
(pRL0CMV; Promega), 100 ng/well of NF-κB Fireﬂy luciferase reporter
plasmid and 700 ng/well of His-FLAG-SQSTM1 construct (either wild-
type or PDB-mutant). 2 μl of the transfection reagent Lipofectamine
2000 (Invitrogen) and 50 μl of Opti-MEM medium (Invitrogen) were
used per well and then cells were incubated at 37 °C, 5.5% CO2. The cells
were lysed 30 h after transfection and luciferase activity was determined
using the Steady-Glo luciferase assay system (Promega) according to the
manufacturer's instructions. A GloMax-96 Microplate Luminometer
(Promega) was used to measure Fireﬂy and Renilla activities. Data were
normalised to Renilla activity and for each mutant expressed relative to
wild-type activity. For each experiment the normalised values of the
quadruplicates were averaged, and data are presented as the mean of
the average values from the four separate experiments ± SD. Statistical
analyses used a one-way ANOVA (Prism5) and a Dunnett's test to
calculate the level of signiﬁcance between wild-type SQSTM1 and
PDB-mutant values. Signiﬁcance was set at p b 0.05. Western blotting
veriﬁed that the expression levels of the different SQSTM1 constructs
were similar aswell as the integrity of the transfected SQSTM1 proteins.
2.4. Protein stability experiments
The stability of transfected His-FLAG-SQSTM1 proteinswas assessed
essentially as described previously [7] except using HEK293 cells. Brief-
ly, cells were transfected with wild-type, P392L or A427D mutant
SQSTM1 constructs and 48 h after transfection, were either lysed
(time 0) or treated with 2 μg/ml cycloheximide to prevent further pro-
tein synthesis. Samples were collected after incubation for a further 24,
48, or 72 h and protein extracts analysed by western blotting with anti-
FLAG or anti-α-tubulin antibodies. After densitometric analysis,
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α-tubulin bands with values at time zero set to 1.0.
2.5. Patients and clinical assessments
The relation between SQSTM1mutations, disease extent and age at
diagnosis was assessed in 1156 PDB patients of whom 766 were from
the UK and had participated in the PRISM study [30] and 390 were re-
cruited from secondary referral centres in Tuscany and Campania in
Italy as previously described [20]. Disease extent was assessed in all pa-
tients by radionuclide bone scan in which the number of affected sites
was counted. Age at diagnosis was obtained by a review of medical
records. Clinical data for patients with truncating mutations (E396X
(n = 6) and Y383X (n = 5)), which both result in complete loss of
the UBA domain, were similar and these genotypes were combined
for statistical analysis. We excluded four compound heterozygotes
from the analysis leaving a ﬁnal study population of 1152.
2.6. Statistical analysis
The relation betweenmutation status, disease extent and age at ﬁrst
diagnosis was assessed by ANOVA. Two analyses were performed; in
the ﬁrst we analysed disease extent and age at ﬁrst diagnosis in relation
to the presence or absence of SQSTM1 mutations (Fig. 3a/b, ﬁrst two
bars); in the second we analysed the same variables in relation to indi-
vidual mutations by ANOVA, and assessed differences between wild-
type and individual mutations by pairwise testing using Tukey's test.
The relation between the ability of different SQSTM1 mutants to acti-
vate basal NF-κB signalling, disease extent and age at ﬁrst diagnosis
was assessed by comparing the mean value of each clinical variable
with the mean value of NF-κB activation using Pearson's correlation.
2.7. Isothermal titration calorimetry (ITC) and circular dichroism (CD)
The unlabelled and 15N-labelled GST-UBA mutants, untagged ubiqui-
tin and 15N-labelled untagged ubiquitin, were expressed and puriﬁed as
described previously [27,32]. Thrombin cleavage was used to remove
the GST-tag from the glutathione-Sepharose-immobilised UBA domain
fusions. Puriﬁcation of the eluted proteins by gel ﬁltration (Superdex75;
GE Healthcare) in 30 mM potassium phosphate, 100 mM NaCl, pH 7,
allowed fractions of puriﬁed UBA domains to be concentrated by
lyophilisation. Fractions were then subsequently desalted on a 5 × 5 ml
HiTrap™ desalting column (GE Healthcare) before lyophilisation.
Methods for isothermal titration calorimetry (ITC) have been de-
scribed previously [32]. In brief, ITC was carried out using a MicroCal
VP-ITC instrument. 5 μl of wild-type UBA or I424S-UBA stock solution
(250 mM) in 50 mM potassium phosphate buffer, pH 7.0, 50 mM NaCl,
was sequentially injected into the ITC cell at 298 K, and the endothermic
heat pulse was measured. Data were corrected for the effects of buffer
mixing by including an enthalpy of mixing as an iterated variable. The
data were analysed using the MicroCal Origin software to determine
Kdim using a standard nonlinear least-squares regression analysis [27].
Far UV circular dichroism (CD) spectra were collected on an Ap-
plied PhotoPhysics Pi-Star™ spectrophotometer at 298 K using a
0.5 mm (80–110 μM solutions) path length quartz cuvette over a
wavelength range from 180 to 260 nm.
2.8. Protein NMR titration experiments
NMR experiments were performed on an AVANCE800 Bruker spec-
trometer using a TXI cryoprobe and standard pulse sequences with wa-
tergate solvent suppression on a cryoprobe. Protein buffer solutions
consisted of 25 mM potassium phosphate buffer, 25 mM NaCl, 5% (v/v)
D2O, 0.02% (w/v) sodium azide, pH 7.0. NMR titration studies of
15N-labelled ubiquitin with unlabelled I424S-UBA or unlabelled wild-
type-UBA domain were performed at 298 K and 1H–15N–HSQC spectrawere collected up to a UBA:ubiquitin ratio of 6:1. Chemical shift pertur-
bations (CSPs)were calculated asΔδHSQC= [(ΔδH)2+ (ΔδN/5)2]1/2 [24],
where ΔδH and ΔδN are the observed shift perturbations in the 1H and
15N dimension of the HSQC spectrum. Binding isotherms were con-
structed and analysed from the dependence of ΔδHSQC on [UBA]TOT.
CSPs (N0.1 ppm) were ﬁtted to a 1:1 binding model using the pro-
gramme KaleidaGraph to derive an apparent Kobs. From ﬁts
shown in Fig. 5c, the Kobs were calculated averaged over 4–5 differ-
ent residues. Since Kobs = Kd2/Kdim, where Kd is the UBA-Ub dissoci-
ation constant and Kdim the dimer dissociation constant, using Kdim
values derived from the ITC experiments the Kd values could be
calculated.
3. Results
3.1. Position of mutations and effects on ubiquitin-binding
The positions of the I424, A427 and previously characterised PDB-
associated G425 mutation sites are shown mapped on to the SQSTM1
UBA monomer structure in Fig. 1a and are in close proximity within
the tertiary structure. I424 and G425 are localised at the C-terminal
end of loop 2, and A427 is located at the N-terminus of helix 3 of the
UBA domain. The C-terminal end of helix 3 is the common interaction
surface for both ubiquitin-binding and UBA domain dimerisation [27].
We ﬁrst examined the effects of the I424S and A427D mutations on
SQSTM1's ubiquitin-binding function in vitro using pull-down assays.
In this case recombinant GST-SQSTM1 proteins were incubated with
glutathione (g), control (c), and ubiquitin-Sepharose (u) beads at
37 °C, pH 7.5. Here G425R-mutant GST-SQSTM1 acts as a control for
complete loss of ubiquitin-binding [29]. Both the I424S and A427Dmu-
tants were also associated with a reduced ability to bind to ubiquitin
(Fig. 1b). Notably however, although the denatured molecular weight
of the A427D-mutant GST-SQSTM1 was consistent with that of the
wild-type protein and other (I424S, G425R) mutants, longer exposures
of western blots were required to detect protein bands in the
glutathione-Sepharose-bound samples, suggesting reduced stability or
solubility of the A427D-mutant protein.
3.2. Effects of mutations on NF-κB signalling
The effects of over-expressing mutant SQSTM1 proteins on the acti-
vation of basal NF-κB signalling in HEK293T cells were assessed
(Fig. 2a). Previous studies using the same approach have shown that dif-
ferent PDB-associated UBA domain missense mutants of SQSTM1, in-
cluding G425R, increase basal NF-κB activity relative to wild-type
which itself is associated with repression of signalling compared to
empty vector control [7]. In addition, we also previously noted that
truncating mutants of SQSTM1 (e.g. E396X), suggested to be associated
with more severe PDB than missense mutants [6,7], gave the greatest
level of activation of basal NF-κB activity in reporter assays [22]. Here
we examined the effects of expression of not only the I424S and
A427D mutants, but also in parallel several other PDB-associated
SQSTM1 UBA domain mutants, on basal NF-κB activity. The other mu-
tants P392L, E396X, M404V and G425R were chosen because they
were the most common mutations within the PRISM study [15]. Like
other PDB-associated mutants tested, both I424S and A427D activated
basal signalling, relative to wild-type SQSTM1 (Fig. 2a), although the
values for the P392L mutant did not reach signiﬁcance by one-way
ANOVA and Dunnett's test (p= 0.23); notably A427D-SQSTM1was as-
sociatedwith the greatest level of activation (relative towild-type) of all
PDB mutants tested to date. In contrast to the observations with the
GST-SQSTM1 proteins expressed in E. coli, comparable steady-state
levels of all transfected proteins, including the A427Dmutant, were de-
tected in these mammalian cells (Fig. 2b). Consistent with these obser-
vations, analyses in HEK293 cells demonstrated that SQSTM1mutations
had only minor effects on protein stability over the course of 72 h (see
Fig. 1. a. SQSTM1 UBA domain structure (from the dimeric structure PDB accession code: 2knv) with the PDBmutation sites I424, G425 and A427 highlighted.α1-3 refer to the three he-
lices. b. In vitro ubiquitin-binding assays showing the effects of the I424S andA427Dmutations onGST-SQSTM1ubiquitin-binding function.Mutations as indicated (orwild-type,wt)were
introduced into the full-length GST-SQSTM1 sequence and pull-down assays were performed at 37 °C. Bacterial lysates containing the GST-SQSTM1 fusions were incubated with
glutathione- (G), control- (C) and ubiquitin-Sepharose (Ub) beads and captured proteins were detected by western blotting (anti-SQSTM1 antibodies). The G425R mutation has previ-
ously been shown to cause complete loss of ubiquitin-binding function in similar assays. c. Puriﬁcation of bacterial expressed GST-UBA SQSTM1 proteins or GST only. Bacterial over-
expressions of GST-UBA proteins were afﬁnity puriﬁed using glutathione-Sepharose beads. The products from the puriﬁcation were loaded onto a 5-20% gradient SDS-PAGE gel which
was subsequently stained with Coomassie blue.
995A. Goode et al. / Biochimica et Biophysica Acta 1842 (2014) 992–1000Supplementary data Fig. S1), and importantly these did not correlate
with the ability of different mutant SQSTM1 proteins to activate NF-κB
activity in our reporter assays. Further, co-immunoprecipitation exper-
iments found no evidence of altered interactions of the transfected
SQSTM1 proteinswith endogenous aPKC proteins (data not shown), in-
dicating that the effects of the mutations are not mediated through al-
tered interactions with these critical regulators of NF-κB signalling.
3.3. Genotype–phenotype analyses
We went on to investigate possible associations between the ability
of different UBA domain mutants of SQSTM1 to activate basal NF-κB sig-
nalling and clinical markers of disease severity, including the age at ﬁrst
diagnosis and number of affected sites as determined by radionuclide
bone scan. The relation between mutation type, age at ﬁrst diagnosis
and number of affected sites is shown in Fig. 3. Patients with SQSTM1
mutations had signiﬁcantly more extensive disease (Fig. 3a) and an ear-
lier age at ﬁrst diagnosis (Fig. 3b) than those without mutations. The
number of affected sites and age at ﬁrst diagnosis also varied by muta-
tion type but pairwise comparisons revealed few signiﬁcant differences
between genotypes probably because of the small sample size for most
mutations. Although the A427D mutation was associated with an in-
crease in number of affected sites relative to all other mutants except
I424S, it is notable that thismutation is found in only two (related) indi-
viduals (with 5 and9 affected sites, respectively). Therewas a signiﬁcant
association between the ability of different mutations to activate basal
NF-κB signalling in vitro and average number of affected sites (r =
0.827, p = 0.022) (Fig. 3c), but no signiﬁcant association between NF-
κB activation and age at ﬁrst diagnosis (r = −0.08, p = 0.86) (data
not shown). As the clinical data related to the A427D mutation again
came from only two related individuals we also repeated the Pearson's
correlation of NF-κB activation and average number of affected sites
without the A427D values, and although the correlation remained posi-
tive (0.43) the result was no longer signiﬁcant (p = 0.395), primarilybecause we are dealing with only limited observations since we corre-
lated mean NF-κB expression with mean number of lesions (data not
shown). However, repeating this analysis with every patient in the
study population assigned a NF-κB score according to mutation status
(which makes use of all study data) and relating this to affected bone
numbers, the result was highly signiﬁcant both when we included all
patients (r = 0.277, p b 0.0001) and also when the two patients with
A427D mutations were excluded (r = 0.244, p b 0.001) (data not
shown).
3.4. Impact of mutations on UBA domain structure and dimerisation
We next sought to understand the structural basis of the effects of
the I424S and A427D mutants on SQSTM1's ubiquitin-binding function
revealed in the pull-down assays (Fig. 1b), and in particular, given the
close proximity of these mutations to the site affected by the previously
characterised G425Rmutant, whether common or distinct mechanisms
are manifested. These structural analyses necessitated that we focussed
on the UBA domain sequences alone (residues 387–436) expressed in
E. coli. Prior to thrombin cleavage to remove the GST tag, puriﬁed GST-
A427D-UBAwas found by SDS PAGE to be present at much lower levels
than the wild-type or I424S/G425R variants (Fig. 1c). In addition, lower
molecular weight bands, presumably representing truncated UBA se-
quences generated by adventitious proteolysis, were evident for the
A427D mutant. After thrombin cleavage, although the wild-type and
I424SmutantUBAdomains yielded a signiﬁcant amount of puriﬁed pro-
tein (3–4mg/l culture), no protein of the expected denaturedmolecular
weight (as determined by SDS PAGE) was recovered for the A427Dmu-
tant (not shown). In addition, electrospray ionisation-mass spectrome-
try (ESI-MS) analyses as previously described [33] conﬁrmed the
expected mass values of the wild-type, I424S and G425R-UBA domains,
but the A427D-UBA domain could not be detected (not shown). We
speculate that this could be due to the A427Dmutation causing a reduc-
tion in stability or solubility of the SQSTM1-UBA, as was noted for the
Fig. 2. a. Effects of wild-type and PDBmutant SQSTM1 over-expression on basal NF-κB ac-
tivity. HEK293T cells were co-transfectedwith His-FLAG-SQSTM1 pcDNA3.1 constructs as
indicated or empty vector (ev) pcDNA3.1 control along with NF-κB Fireﬂy luciferase re-
porter and control Renilla luciferase construct [36]. Cells were harvested 30 h after trans-
fection and luciferase activity was measured. Fireﬂy luciferase values were normalised to
Renilla values. Experimentswere performed inquadruplicate and assayswere repeated on
4 separate occasions. Data is displayed as mean± SDwith p values indicating signiﬁcance
of difference compared with wild-type as indicated. The A427D mutant gave had the
highest level of activation of all PDB mutants tested to date. b. Western blotting analysis
(anti-SQSTM1, anti-β-actin) showed comparable expression levels of the different His-
FLAG-SQSTM1 constructs (HF-SQSTM1) from a representative set of samples from a single
NF-κB reporter assay.
Fig. 3. Clinical data for UK and Italian PDB patients in this study. a. Mean number of affect-
ed sites +/− SEM and b. mean age at ﬁrst diagnosis for PDB patients with the indicated
genotypes+/− SEM.Wild-type refers to PDBpatientswith no SQSTM1mutations;mutant
refers to all SQSTM1mutations combined. The number in brackets refers to number of PDB
patients with the given mutation. ***p b 0.001 from wild-type, #p b 0.05 from all other
mutants except I424S, and ‡p b 0.05 from P392L mutant. c. Pearson's correlation analysis
was used to investigate the relationship between the ability of different SQSTM1mutants
to activate basal NF-κB signalling in reporter assays (relative luciferase activity) and dis-
ease extent (number of affected sites) in 1152 PDB patients with the correspondingmuta-
tions. Clinical data for “E396X” represents that from combining data for patients with
truncating mutations (E396X and Y383X).
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the UBA domain NMR structure [27] indicates that A427 is a buried res-
idue that stabilises the UBA domain through hydrophobic packing of
helix 3. A427 is highly conservedwithin the SQSTM1 sequence of differ-
ent species. The A427D-UBAmutation is likely to be highly destabilising
as a consequence of the greater steric bulk of Asp and the large energetic
penalty due to burying the polar side chain from access to solvent. This
analysis is consistent with the inability to isolate puriﬁed material.
Molecular modelling (not shown) also predicted that the I424S mu-
tation is likely to affect the packing of helix 3 within the UBA domain
structure, but in contrast to the A427D mutant, the I424S-UBA mutant
could be expressed and readily isolated from E. coli. We thus were
able to perform detailed structural analyses of this UBA mutant. We
ﬁrst investigated the effects of the I424Smutation on formation of a sta-
ble UBA dimer, a feature of the wild-type UBA domainwhich negatively
regulates ubiquitin-binding [27]. ITC was used to determine the Kdim
value for dimer dissociation from dilution experiments (see Fig. 4c). En-
dothermic heat pulses were observed after injection of the protein into
buffer solution. Kdim values indicate that the I424S mutant is a 10-fold
weaker dimer (Kdim = 19.8 ± 1.0 μM compared to wild-type UBA
analysed under identical conditions (Kdim = 2.0 ± 0.3 μM), in contrast
with our previous observations that showed that the G425R mutant is
a slightly stronger dimer than wild-type [24].
NMR experiments were performed on the 15N-isotopically labelled
I424S-UBA domain mutant to examine the effects on UBA domainstructure. Initial analysis at a protein concentration of 750 μM, well
above the Kdim, ensured that the mutant was dimeric, permitting close
comparison with analogous data for wild-type UBA. The 15N-HSQC
NMR ‘footprint’ for each protein provides a sensitive residue-speciﬁc
probe of changes in protein structure. Comparing the I424S-UBA mu-
tant to the wild-type UBA spectra, 11 out of 50 residues showed signif-
icant (N0.1 ppm) CSPs indicative of structural changes (Fig. 4a). The
Fig. 4.Biophysical data demonstrating the structural differences betweenwild-type and I424S-UBAdomains of SQSTM1. a.Weighted chemical shift perturbations (CSPs) for theUBAdimer
([UBA] ~ 750 μM; CSP, weighted average from 1H and 15N shifts) showing the residues that are perturbed when introducing the I424S mutation into the UBA domain, compared to wild-
type. All CSPs N 0.1 ppm are deemed signiﬁcant (with the 0.2 CSP threshold highlighted with a dotted line), indicating extensive structural effects propagated from the mutation site.
b. CSPs from (a) mapped on to the UBA surface showing the position of surface residues that are perturbed by the I424S mutation; darker red represents bigger CSP values (PDB structure
2KNV) c. Dimer dissociation isotherms ofwild-type (wt) and I424S-UBAderived from the integrated heat absorbance proﬁle of ITC dilution experiments. d. Far-UVCD spectra for the re-folded
wild-type-UBA (wt, solid line) and I424S mutant (dotted line) recorded at concentrations between 80 and 110 μM showing a helical spectrum consistent with fully folded dimeric structure.
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mapped onto the surface of the wild-type UBA dimer structure
(Fig. 4b). This structural analysis shows that not only is the I424S change
affecting the local environment around themutation site, but also exerts
effects across thewhole domain. Although themutation occurs at theN-
terminus of helix 3, large effects (CSPs N 0.2 ppm) are propagated along
the helix signiﬁcantly disrupting many of the critical residues required
for both UBA dimerisation and ubiquitin-binding. Residues L428, T430,
and I431 all show CSPs over 0.1 ppm and form important contacts
across the dimer interface. I431 and L428 are key residues on the
ubiquitin-binding surface of the UBA domain. Further away from the
mutation site, residues within helix 1 (Q400, M401 and L402), loop 1
(S406 and E409) and helix 2 (E418) all show CSPs over 0.1 ppm;
many of these residues are required to stabilise the UBA dimer interface
[27]. In contrast, more local effects were previously noted for the G425R
mutant (only residues I424-A427, D429 and K435 have CSPs N 0.1 ppm)
suggesting only small structural changes adjacent to this mutation site
[24], consistent with the location of this residue on the protein surface.
3.5. NMR insights into impact of mutations on UBA dimerisation
We further investigated the dimer–monomer equilibrium of the
UBA domain using NMR by recording 2D-HSQC spectra at concentra-
tions below the Kdim values where the dimer is fully dissociated to the
biologically active monomeric form [27]. As previously reported, wild-
type UBA at b5 μM concentration shows two sets of well dispersed
peaks corresponding to an equilibrium between the stable dimer and
a folded monomer (see Supplementary data Fig. S2 part b). In contrast,
and as a control, we showed that the engineered T419K-UBA mutant,which has a destabilised dimer interface, retains its structural integrity
as a folded monomer at 10 μM [27] (Supplementary data Fig. S2
part c). In spectra of the I424S-UBA mutant at 10 μM concentrations,
where the ITC results predict the exclusive presence of monomer, we
observed a poorly dispersed spectrum with peaks signiﬁcantly broad-
ened and clustered around a narrow chemical shift range (Supplemen-
tary data Fig. S2 part d). This spectrum is highly indicative of a largely
unfolded protein, suggesting that whilst the dimer retains a large part
of its structural integrity, stabilised by contacts at the dimer interface,
in isolation the monomeric form of the I424S-UBA is unstable and con-
verts to the unfolded state. The process was entirely reversible, with
lyophilisation of dilute solutions of I424S-UBA and concentration of
samples to N100 μM showing that the mutant readily reformed the
dimer structure. A set ofwell dispersedpeaks in the 15N-HSQC spectrum
and a helical CD spectrum (Fig. 4d)was consistent with that of thewild-
type UBA dimer at similar sample concentrations (80–110 μM). ESI-MS
showed no sign of protein degradation over this period (data not
shown), indicative of an equilibrium between different folded and un-
folded states.
3.6. Impact of mutations on ubiquitin-binding
Finally, we used NMR to probe the interaction of the I424S-UBA do-
main with ubiquitin. Titration of the unfolded 15N-labelled I424S-UBA
monomer at 10 μM concentration with unlabelled ubiquitin, up to a
40:1 excess of ubiquitin to I424S-UBA, resulted in very minor perturba-
tions to the spectra (not shown). This is indicative of weak binding of
the monomeric unfolded mutant UBA to ubiquitin, consistent with
pull-down experiments. In contrast, the wild-type UBA monomer
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demonstrating strong binding at low concentrations of protein. The ef-
fects of the I424Smutation on the UBA domain's ability to bind to ubiq-
uitin were also studied in NMR titrations with 15N-labelled ubiquitin as
the spectroscopic probe and unlabelledUBAdomains as the ‘silent’ part-
ner. Spectra were recorded up to an excess ratio of 6:1 UBA:ubiquitin,
but the I424S-UBA showed only small CSP effects on K48 and L71
(0.05 to 0.1 ppm) of 15N-ubiquitin compared with the larger number
of signiﬁcant perturbations observed for wild-type UBA (Fig. 5d). In at-
tempts to quantify the effects of the I424Smutation on theUBA-binding
afﬁnity we constructed binding isotherms for the two NMR titration ex-
periments with 15N-ubiquitin. From ﬁts shown in Fig. 5c, the Kobs were
calculated; Kobs = 189 μM (wild-type UBA) and Kobs = 709 μM (I424S-
UBA), averaged over 4 different residues. Fitting the data to allow for a
two-step process involving UBA dimer dissociation and folding by
ubiquitin-binding we estimated that the mutant binds at least 6-fold
weaker than the wild-type UBA (wild-type UBA Kd = 19 μM and
I424S-UBAKd= 119 μM). This is likely to be an underestimate of the re-
duction in afﬁnity since the large differences in the limiting CSPs for res-
idues in the fully bound state for the I424Smutant versuswild-typeUBA
are consistent with the mutant forming a much weaker binding inter-
face with only a small set of the contacts observed for the wild-type
UBA. For example, I13, I44 and V70, which form thewidely reported ca-
nonical UBA hydrophobic binding surface of ubiquitin, are largely un-
perturbed, suggesting that the loss of structural integrity in the I424S
mutant is no longer compatible with binding to the ubiquitin I44
patch. The free energy of the binding interaction is not sufﬁcient to
pull the unfolded monomer into a folded bound form. In contrast, our
data show, in the context of the UBA domain dimer, many more con-
tacts are formed along helix 2 making the dimerisation interface much
stronger than the UBA/ubiquitin interaction.Fig. 5. Portion of the 1H–15N-HSQC spectra from titrating ubiquitin (180 μM)with increasing conc
The spectra focus on the perturbation to the shift of the peak for V70 showing little movement f
termined from CSPs (N0.1 ppm)measured from the titrations of 15N-ubiquitin (180 μM)with eit
bindingmodel was usedwith the programme KaleidaGraph to derive an apparent Kobs. The grap
for both wild-type-UBA (black) and I424S-UBA (white, CSPs are small and overlay). d.Weighted
type (wt) UBA (white bars) or I424S-UBA (black bars) at a ﬁnal ratio of 1:6 (ubiquitin:UBA) at 2
[UBA]TOT. All CSPs above 0.1 are deemed signiﬁcant. The I424S-UBA mutant resulted in very min4. Discussion
PDB is the second most common metabolic bone disease after oste-
oporosis. The precisemechanisms that underlie PDB aetiology are yet to
be established but there is considerable evidence that SQSTM1 muta-
tions play a central role [3,4,6,7,11,22,23]. Initially all SQSTM1mutations
were thought to contribute to the pagetic phenotype through increases
in osteoclastogenesis and osteoclast activity, via activation of RANK-NF-
κB signalling [7,11,22,23]. Another common property of theﬁrst mutant
SQSTM1proteins analysedwas impaired binding to ubiquitin in vitro [7,
22,29,31]. Herewe found that both the I424S and A427Dmutations also
impair SQSTM1's ability to bind to ubiquitin, and when over-expressed
mutants are associated with activation of basal NF-κB signalling in re-
porter assays. Indeed all six of the PDB-mutant SQSTM1 sequences test-
ed (covering the most common mutations found within the PRISM
study [15]) were able to activate basal NF-κB activity, relative to wild-
type SQSTM1, in our HEK293T cell model. We also present evidence
for an association between the ability of the different UBA domain mu-
tants to activate basal NF-κB signalling and number of affected sites in
1152 PDBpatients. Our analyses did not take into account secular trends
indicating a progressive decrease in the number of affected skeletal sites
in PDB [34] although we did note that most patients with truncating
mutations (E396X and Y383X) had a severe phenotype even in younger
patients. Signiﬁcantly 12/13 of the PDB patients in our study with trun-
cating or A427D mutations, associated with the highest levels of NF-κB
activity in reporter assays, exhibited polyostotic PDB and in a previous
study a similar phenotype was noted for three patients with the
Y383X mutation [10]. Further the A427D mutant, associated with a
high number of affected sites in the two reported (albeit related) car-
riers (7.00 ± 2.8 affected pagetic sites compared to 3.60 ± 2.6 sites in
SQSTM1 mutation carriers collectively within the cohort [14]), gave aentrations of a. I424S-UBA and b. wild-type-UBA, at 298 K up to a ubiquitin:UBA ratio of 1:6.
or binding of I424S-UBA and a more signiﬁcant shift for wild-type. c. Binding isotherms de-
her wild-type (wt) UBA or I424Smutant to a ﬁnal ratio of ubiquitin:UBA 1:6 at 298 K. A 1:1
h shows four representative residues of which the CSPswere ﬁtted to the 1:1 bindingmodel
CSP data showing the residues of 15N-ubiquitin (180 μM) that are perturbed by either wild-
98 K. Binding isotherms were constructed and analysed from the dependence of ΔδHSQC on
or perturbations to the spectra.
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analysed to date, including the E396X truncating mutant. Thus, despite
the caveat that other gene variants can inﬂuence severity in PDB with
and indeed without SQSTM1 mutations [20] at least in some cases (i.e.
forUBAdomainmutations) the SQSTM1 status alonemayexert signiﬁcant
effects on disease phenotype via changes in RANK-NF-κB signalling. Our
ﬁndings are however counter to the notion of a direct relationship be-
tween SQSTM1 protein function (i.e. ubiquitin-binding activity) and dis-
ease severity – in the truncating mutant the UBA domain is completely
lost, which would clearly have a more marked effect on protein function
than a missense mutation e.g. although weaker, we show that I424S mu-
tation still has ameasurable ubiquitin-binding afﬁnity). In fact analyses of
other PDB-associatedmutants demonstrate that the relationshipbetween
SQSTM1 protein function, NF-κB activity and PDB severity is more com-
plex than initially anticipated. Some non-UBA domain mutants have no
effect on ubiquitin-binding function but can activate NF-κB activity [11],
and we have very recently described a non-UBA domain mutation
which affects neither SQSTM1's ubiquitin-binding function nor its ability
to regulate NF-κB activity in reporter assays [35]. Clearly further studies
are required in this area, including in more physiologically-relevant cell
models and including correlationswith other aspects of SQSTM1 function.
Our initial goal was to characterise both the I424S and A427Dmutant
UBAdomains in structural detail althoughnotably the latterwas not ame-
nable to biophysical analysis. Over-expression of the GST-A427D-UBA se-
quence led to rapid degradation in E. coli, consistent with the A427D
mutation destabilising the three-helix bundle of the UBA monomer ren-
dering the unfolded protein highly susceptible to proteolysis. This is sim-
ilar to the M404V/T UBA mutants which we have previously reported to
be associated with poor expression levels (as UBA only sequences),
lower solubility, and aggregation effects consistent with destabilisation
of the UBA domain [24]. However, full-length eukaryotic and prokaryotic
A427D-SQSTM1 sequences were detectable by western blotting, and we
found no overtly detrimental effects of the mutation on protein half-life
inmammalian cells, suggesting that theremaybe an intrinsic stabilisation
of the UBA domain of SQSTM1 within the full-length protein.
Although the I424S and previously characterised G425Rmutants are
located in close proximity within the UBA tertiary fold they exertFig. 6.Equilibrium showing inter-conversion between the SQSTM1UBA dimer (left),monomer (
the relative stabilities of these species. Only the foldedmonomer is compatible with binding to
able to reduce Kd via a number ofmechanisms that either directly perturb theUBA:ubiquitin int
(I424S). Both reduce the population of the activemonomeric UBA for binding to ubiquitin. I424S
under physiological conditions. In contrast, G425R not only increases the stability of the dimer c
and electrostatic effects.distinct effects on protein function and structure. As illustrated in
Fig. 6, we have established that the SQSTM1 UBA is involved in a com-
plex equilibrium between an inactive dimeric form, an active
ubiquitin-bindingmonomer and an inactive unfolded state. Itwould ap-
pear that PDB mutations can perturb these equilibria in a manner that
both directly and indirectly affects the binding afﬁnity of the active
monomer. Wild-type SQSTM1 exists in equilibrium where the stability
of the UBA dimer regulates ubiquitin-binding by sequestering the bio-
logically active monomeric UBA [27]. The dimer interface protects the
ubiquitin-binding surface making UBA dimerisation and ubiquitin-
binding competitive recognition events. In contrast to the neighbouring
loop 2 mutant (G425R) which stabilised the UBA dimer, the I424S mu-
tation produces a 10-fold reduction in dimer stability with extensive
structural perturbations to helix 3 and core packing interactions. In
this respect, the PDB-associated I424S mutation appears to result in
similar effects on SQSTM1 structure as the S399P mutation which
destabilises helix 1 [24]. NMR titrations of 15N-ubiquitin with the
I424S-UBA revealed that the mutant also resulted in at least a 6-fold
weaker binding afﬁnity for ubiquitin than that of wild-type UBA. More-
over, not only are the limiting CSP effects much smaller for the mutant
UBA, indicative of a much weaker binding interface, but the canonical
hydrophobic patch on the surface of ubiquitin (I13, I44 and V70) ap-
pears to be largely unperturbed by the interaction with the I424S-UBA
mutant, also suggesting loss of binding speciﬁcity. The I424S mutation
involves a key residue in helix 3 that packs against helix 1 and forms
part of the stabilising hydrophobic core of the three-helix bundle.
NMR studies show that themonomeric UBA domain is largely unfolded
in isolation, although it is stabilised at higher concentrations through
formation of the dimeric structure. Thus, both I424S and A427D are
clear examples of PDB mutations that have such dramatic effects on
the stability and structural integrity of the folded UBA domain structure
that they are no longer able to directly interact with ubiquitin with any
signiﬁcant binding afﬁnity. In contrast, the G425R mutation affects a
surface exposed residue and results in none of the associated effects
on the stability of the UBAmotif. Substitution of G with a bulky charged
R side chain (G425R) appears to affect the steric complementarity of the
UBA binding surface on helix 3 [24].centre) and an unfolded state (right), with the equilibrium constants Kdim andKeq deﬁning
ubiquitin via the I44 hydrophobic patch with a measurable afﬁnity, Kd. PDBmutations are
erface (I424S, G425R) or indirectly stabilise either the dimer (G425R) or the unfolded state
appears to destabilise both the dimer andmonomer, partially favouring the unfolded state
ompared with wild-type UBA, but also directly affects the binding interface through steric
1000 A. Goode et al. / Biochimica et Biophysica Acta 1842 (2014) 992–1000In summarywe show that both the I424S andA427D PDB-associated
SQSTM1 mutants exhibit impaired ubiquitin-binding function in pull-
down assays and dysregulated basal NF-κB signalling in luciferase re-
porter assays, and ﬁnd that there is a signiﬁcant correlation between
the ability of different UBA domain mutants of SQSTM1 to regulate
NF-κB activity in cell models and extent of PDB in patients with the cor-
respondingmutations. Further, we report loss of both structural integri-
ty and stability of the I424S-UBA domain in biophysical experiments.
The I424S and A427D mutants exert differing effects on SQSTM1 func-
tion relative to other PDB mutants, demonstrating diverse molecular
mechanisms operating in the aetiology of PDB.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.03.006.
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